{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T08:57:46Z","timestamp":1780045066136,"version":"3.53.1"},"reference-count":30,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"24","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2007,8,20]]},"abstract":"<jats:sec><jats:title>Purpose<\/jats:title><jats:p> To construct a clinical nomogram instrument to estimate individual risk for having prostate cancer (PC) for patients undergoing prostate specific antigen (PSA) screening, using all risk factors known for PC. <\/jats:p><\/jats:sec><jats:sec><jats:title>Patients and Methods<\/jats:title><jats:p> We conducted a cross-sectional study of 3,108 men who underwent a prostate biopsy, including a subset of 408 volunteers with normal PSA levels. Factors including age, family history of PC (FHPC), ethnicity, urinary symptoms, PSA, free:total PSA ratio, and digital rectal examination (DRE) were incorporated in the model. A nomogram was constructed to assess risk for any and high-grade PC (Gleason score \u2265 7). <\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p> Of the 3,108 men, 1,304 (42.0%) were found to have PC. Among the 408 men with a normal PSA (&lt; 4.0 ng\/mL), 99 (24.3%) had PC. All risk factors were important predictors for PC by multivariate analysis (P, .01 to .0001). The area under the curve (AUC) for the nomogram in predicting cancer, which included age, ethnicity, FHPC, urinary symptoms, free:total PSA ratio, PSA, and DRE, was 0.74 (95% CI, 0.71 to 0.81) and 0.77 (95% CI, 0.74 to 0.81) for high-grade cancer. This was significantly greater than the AUC that considered using the conventional screening method of PSA and DRE only (0.62; 95% CI, 0.58 to 0.66 for any cancer; 0.69; 95% CI, 0.65 to 0.73 for high-grade cancer). From receiver operating characteristic analysis, risk factors including age, ethnicity, FHPC, symptoms, and free:total PSA ratio contributed significantly more predictive information than PSA and DRE. <\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p> In a PC screening program, it is important to consider age, family history of PC, ethnicity, urinary voiding symptoms, and free:total PSA ratio, in addition to PSA and DRE. <\/jats:p><\/jats:sec>","DOI":"10.1200\/jco.2007.10.6450","type":"journal-article","created":{"date-parts":[[2007,8,17]],"date-time":"2007-08-17T22:23:29Z","timestamp":1187389409000},"page":"3582-3588","source":"Crossref","is-referenced-by-count":136,"title":["Assessing Individual Risk for Prostate Cancer"],"prefix":"10.1200","volume":"25","author":[{"given":"Robert K.","family":"Nam","sequence":"first","affiliation":[{"name":"From the Division of Urology, Departments of Radiation Oncology and Pathology, Sunnybrook Health Sciences Centre; Division of Urology, Department of Medical Imaging, University Health Network; Department of Public Health Sciences, University of Toronto, Toronto, Canada; and Quantitative Health Sciences, The Cleveland Clinic, Cleveland, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ants","family":"Toi","sequence":"additional","affiliation":[{"name":"From the Division of Urology, Departments of Radiation Oncology and Pathology, Sunnybrook Health Sciences Centre; Division of Urology, Department of Medical Imaging, University Health Network; Department of Public Health Sciences, University of Toronto, Toronto, Canada; and Quantitative Health Sciences, The Cleveland Clinic, Cleveland, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence H.","family":"Klotz","sequence":"additional","affiliation":[{"name":"From the Division of Urology, Departments of Radiation Oncology and Pathology, Sunnybrook Health Sciences Centre; Division of Urology, Department of Medical Imaging, University Health Network; Department of Public Health Sciences, University of Toronto, Toronto, Canada; and Quantitative Health Sciences, The Cleveland Clinic, Cleveland, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Trachtenberg","sequence":"additional","affiliation":[{"name":"From the Division of Urology, Departments of Radiation Oncology and Pathology, Sunnybrook Health Sciences Centre; Division of Urology, Department of Medical Imaging, University Health Network; Department of Public Health Sciences, University of Toronto, Toronto, Canada; and Quantitative Health Sciences, The Cleveland Clinic, Cleveland, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.S.","family":"Jewett","sequence":"additional","affiliation":[{"name":"From the Division of Urology, Departments of Radiation Oncology and Pathology, Sunnybrook Health Sciences Centre; Division of Urology, Department of Medical Imaging, University Health Network; Department of Public Health Sciences, University of Toronto, Toronto, Canada; and Quantitative Health Sciences, The Cleveland Clinic, Cleveland, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sree","family":"Appu","sequence":"additional","affiliation":[{"name":"From the Division of Urology, Departments of Radiation Oncology and Pathology, Sunnybrook Health Sciences Centre; Division of Urology, Department of Medical Imaging, University Health Network; Department of Public Health Sciences, University of Toronto, Toronto, Canada; and Quantitative Health Sciences, The Cleveland Clinic, Cleveland, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. Andrew","family":"Loblaw","sequence":"additional","affiliation":[{"name":"From the Division of Urology, Departments of Radiation Oncology and Pathology, Sunnybrook Health Sciences Centre; Division of Urology, Department of Medical Imaging, University Health Network; Department of Public Health Sciences, University of Toronto, Toronto, Canada; and Quantitative Health Sciences, The Cleveland Clinic, Cleveland, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Sugar","sequence":"additional","affiliation":[{"name":"From the Division of Urology, Departments of Radiation Oncology and Pathology, Sunnybrook Health Sciences Centre; Division of Urology, Department of Medical Imaging, University Health Network; Department of Public Health Sciences, University of Toronto, Toronto, Canada; and Quantitative Health Sciences, The Cleveland Clinic, Cleveland, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven A.","family":"Narod","sequence":"additional","affiliation":[{"name":"From the Division of Urology, Departments of Radiation Oncology and Pathology, Sunnybrook Health Sciences Centre; Division of Urology, Department of Medical Imaging, University Health Network; Department of Public Health Sciences, University of Toronto, Toronto, Canada; and Quantitative Health Sciences, The Cleveland Clinic, Cleveland, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael W.","family":"Kattan","sequence":"additional","affiliation":[{"name":"From the Division of Urology, Departments of Radiation Oncology and Pathology, Sunnybrook Health Sciences Centre; Division of Urology, Department of Medical Imaging, University Health Network; Department of Public Health Sciences, University of Toronto, Toronto, Canada; and Quantitative Health Sciences, The Cleveland Clinic, Cleveland, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"R1","unstructured":"Bunting PS, Goel V, Williams JI, et al: Prostate-specific antigen testing in Ontario: Reasons for testing patients without diagnosed prostate cancer. Cmaj 160:70,1999-75,"},{"key":"R2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.289.11.1414"},{"key":"R3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198710083171501"},{"key":"R4","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1995.03520280035036"},{"key":"R5","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000139993.51181.5d"},{"key":"R6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa031918"},{"key":"R7","doi-asserted-by":"publisher","DOI":"10.1001\/jama.280.11.975"},{"key":"R8","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(20010615)91:12<2302::AID-CNCR1262>3.0.CO;2-P"},{"key":"R9","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)00159-X"},{"key":"R10","unstructured":"Nam RK, Toi A, Klotz LH, et al: Nomogram prediction for prostate cancer and aggressive prostate cancer at time of biopsy: Utilizing all risk factors and tumour markers for prostate cancer. Canadian J Urol 13:2,2006-10,"},{"key":"R11","doi-asserted-by":"crossref","unstructured":"Catalona WJ, Smith DS, Wolfert RL, et al: Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. Am J Med 274:1214,1995-1220,","DOI":"10.1001\/jama.274.15.1214"},{"key":"R12","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)00695-6"},{"key":"R13","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-05-1226"},{"key":"R14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.11.007"},{"key":"R15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa030660"},{"key":"R16","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)36966-5"},{"key":"R17","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)59889-4"},{"key":"R18","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2004.05150.x"},{"key":"R19","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)67995-5"},{"key":"R20","doi-asserted-by":"crossref","unstructured":"Harrell FE: Regression Modeling Strategies With Applications to Linear Models, Logistic Regression, and Survival Analysis . New York, Springer-Verlag, 2001","DOI":"10.1007\/978-1-4757-3462-1"},{"key":"R21","doi-asserted-by":"publisher","DOI":"10.1016\/S0302-2838(02)00179-3"},{"key":"R22","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000158039.94467.5d"},{"key":"R23","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000087451.64657.fa"},{"key":"R24","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djj131"},{"key":"R25","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1995.03530080042039"},{"key":"R26","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199410133311507"},{"key":"R27","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)65652-2"},{"key":"R28","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000150522.82760.00"},{"key":"R29","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/dji248"},{"key":"R30","doi-asserted-by":"publisher","DOI":"10.1001\/jama.294.1.66"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2007.10.6450","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T20:05:01Z","timestamp":1653509101000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2007.10.6450"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,8,20]]},"references-count":30,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2007,8,20]]}},"alternative-id":["10.1200\/JCO.2007.10.6450"],"URL":"https:\/\/doi.org\/10.1200\/jco.2007.10.6450","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,8,20]]}}}